688302 海创药业
已收盘 12-30 15:00:00
资讯
新帖
简况
海创药业:已按要求提交氘恩扎鲁胺软胶囊新药上市申请补充资料
贝壳财经 · 09:20
海创药业:已按要求提交氘恩扎鲁胺软胶囊新药上市申请补充资料
海创药业:HP568片用于治疗ER+/HER2-晚期乳腺癌的临床试验申请获得美国FDA批准
证券之星 · 08:20
海创药业:HP568片用于治疗ER+/HER2-晚期乳腺癌的临床试验申请获得美国FDA批准
海创药业:氘恩扎鲁胺新药补充资料已提交
金融界 · 08:05
海创药业:氘恩扎鲁胺新药补充资料已提交
海创药业申请HP568片临床试验获FDA批准
财中社 · 08:04
海创药业申请HP568片临床试验获FDA批准
海创药业(688302.SH):HP568片用于治疗ER+/HER2-晚期乳腺癌临床试验申请获美国FDA批准
智通财经 · 07:39
海创药业(688302.SH):HP568片用于治疗ER+/HER2-晚期乳腺癌临床试验申请获美国FDA批准
海创药业(688302)12月24日主力资金净卖出867.42万元
证券之星 · 12-25
海创药业(688302)12月24日主力资金净卖出867.42万元
海创药业-U12月20日主力资金流出214万元 连续3日减仓
市场透视 · 12-20
海创药业-U12月20日主力资金流出214万元 连续3日减仓
海创药业-U12月19日遭主力抛售138万元 环比增加1050.00%
市场透视 · 12-19
海创药业-U12月19日遭主力抛售138万元 环比增加1050.00%
海创药业遭第二大股东再度减持 上市以来亏损超7亿元
新京报 · 12-06
海创药业遭第二大股东再度减持 上市以来亏损超7亿元
海创药业-U创新低 券商建议增持
智选洞察 · 12-05
海创药业-U创新低 券商建议增持
海创药业股东盈创动力拟减持不超过297万股
财中社 · 12-05
海创药业股东盈创动力拟减持不超过297万股
公司热点|频遭二股东减持!多年营收为零 海创药业还要亏损到何时?
读创财经 · 12-04
公司热点|频遭二股东减持!多年营收为零 海创药业还要亏损到何时?
海创药业:股东盈创动力拟减持不超过3%公司股份
证券之星 · 12-04
海创药业:股东盈创动力拟减持不超过3%公司股份
海创药业:第二大股东盈创动力拟减持不超3%公司股份
界面 · 12-04
海创药业:第二大股东盈创动力拟减持不超3%公司股份
海创药业(688302.SH):盈创动力拟减持不超3%股份
智通财经 · 12-04
海创药业(688302.SH):盈创动力拟减持不超3%股份
【机构调研记录】诺安基金调研牧原股份、海创药业等11只个股(附名单)
证券之星 · 12-02
【机构调研记录】诺安基金调研牧原股份、海创药业等11只个股(附名单)
【机构调研记录】安信基金调研海创药业、华测检测等4只个股(附名单)
证券之星 · 12-02
【机构调研记录】安信基金调研海创药业、华测检测等4只个股(附名单)
【机构调研记录】嘉实基金调研歌力思、海创药业等14只个股(附名单)
证券之星 · 12-02
【机构调研记录】嘉实基金调研歌力思、海创药业等14只个股(附名单)
【机构调研记录】兴业基金调研海创药业、福光股份等7只个股(附名单)
证券之星 · 12-02
【机构调研记录】兴业基金调研海创药业、福光股份等7只个股(附名单)
海创药业-U 涨5.44%
智选洞察 · 11-28
海创药业-U 涨5.44%
加载失败,点击重试
公司概况
公司名称:
海创药业股份有限公司
所属行业:
医药制造业
上市日期:
2022-04-12
主营业务:
海创药业股份有限公司是一家基于氘代技术和PROTAC靶向蛋白降解等技术平台,以开发具有重大临床需求的Best-in-class(同类最佳)、First-in-class(国际首创)药物为目标的国际化创新药企业。公司的主要产品为肿瘤、代谢性疾病药品。公司在肿瘤和代谢性疾病领域重点布局,重点搭建了氘代药物研发平台、PROTAC靶向蛋白降解技术平台、靶向药物发现与验证平台与先导化合物优化筛选平台,形成了较强的研发优势和丰富的技术储备。
发行价格:
42.92
{"stockData":{"symbol":"688302","market":"SH","secType":"STK","nameCN":"海创药业","latestPrice":30.47,"timestamp":1735542000000,"preClose":30.22,"halted":0,"volume":724202,"delay":0,"changeRate":0.0083,"floatShares":72724500,"shares":99015600,"eps":-2.1228,"marketStatus":"已收盘","change":0.25,"latestTime":"12-30 15:00:00","open":30.6,"high":30.74,"low":29.85,"amount":22022400,"amplitude":0.0295,"askPrice":30.52,"askSize":1,"bidPrice":30.47,"bidSize":14,"shortable":0,"etf":0,"ttmEps":-2.1228,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1735608600000},"marketStatusCode":5,"adr":0,"adjPreClose":30.22,"symbolType":"stock_kcb","openAndCloseTimeList":[[1735522200000,1735529400000],[1735534800000,1735542000000]],"highLimit":33.24,"lowLimit":27.2,"ibTradeSell":true,"ibTradeBuySell":false,"totalEquity":99015598,"isCdr":false,"pbRate":2.45,"roa":"--","roe":"--","epsLYR":-2.97,"committee":0.5,"marketValue":3017000000,"turnoverRate":0.01,"status":0,"afterMarket":{"amount":0,"volume":0,"close":30.47,"buyVolume":0,"sellVolume":0,"time":1735544038029,"indexStatus":"已收盘 12-30 15:30:00","preClose":30.22},"floatMarketCap":2216000000},"requestUrl":"/m/hq/s/688302/tweets","defaultTab":"tweets","newsList":[{"id":"2495951551","title":"海创药业:已按要求提交氘恩扎鲁胺软胶囊新药上市申请补充资料","url":"https://stock-news.laohu8.com/highlight/detail?id=2495951551","media":"贝壳财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2495951551?lang=zh_cn&edition=full","pubTime":"2024-12-30 17:20","pubTimestamp":1735550414,"startTime":"0","endTime":"0","summary":"新京报贝壳财经讯(记者丁爽)12月30日,海创药业宣布,公司已于近期按照国家药品监督管理局药品审评中心(简称“CDE”)要求提交了氘恩扎鲁胺软胶囊(项目号:HC-1119)新药上市申请的补充资料,目前已进入技术审评阶段,公司团队将与CDE持续保持积极的沟通,争取早日完成新药上市审评程序。据了解,氘恩扎鲁胺软胶囊(项目号:HC-1119)是海创药业自主研发的、治疗转移性去势抵抗性前列腺癌(mCRPC)的1类新药,是第二代雄激素受体(AR)抑制剂恩扎卢胺的氘代药物。编辑 王琳琳校对 陈荻雁","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202412301721199854cce6&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202412301721199854cce6&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["688302","BK0239"],"gpt_icon":0},{"id":"2495159743","title":"海创药业:HP568片用于治疗ER+/HER2-晚期乳腺癌的临床试验申请获得美国FDA批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2495159743","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2495159743?lang=zh_cn&edition=full","pubTime":"2024-12-30 16:20","pubTimestamp":1735546812,"startTime":"0","endTime":"0","summary":"海创药业公告,公司收到美国FDA的临床研究继续进行通知书,公司自主研发的HP568片用于治疗ER+/HER2-晚期乳腺癌的临床试验申请正式获得FDA批准。以上内容为证券之星据公开信息整理,由智能算法生成(网信算备310104345710301240019号),不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024123000020470.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["03347","BK1576","BK1583","BK0239","BK1141","688302"],"gpt_icon":0},{"id":"2495211597","title":"海创药业:氘恩扎鲁胺新药补充资料已提交","url":"https://stock-news.laohu8.com/highlight/detail?id=2495211597","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2495211597?lang=zh_cn&edition=full","pubTime":"2024-12-30 16:05","pubTimestamp":1735545909,"startTime":"0","endTime":"0","summary":"金融界12月30日消息,有投资者在互动平台向海创药业提问:尊敬的董秘:您好。想了解一下,我司氘恩扎鲁胺软胶囊的发补材料是否已经提交?谢谢答复。公司回答表示:公司已于近期按照CDE要求提交了氘恩扎鲁胺软胶囊(项目号:HC-1119)新药上市申请的补充资料,目前已进入技术审评阶段,公司团队将与CDE持续保持积极的沟通,争取早日完成新药上市审评程序。公司将根据项目进展及时披露相关信息。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241230161618ab97b38c&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241230161618ab97b38c&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK0239","688302"],"gpt_icon":0},{"id":"2495597212","title":"海创药业申请HP568片临床试验获FDA批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2495597212","media":"财中社","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2495597212?lang=zh_cn&edition=full","pubTime":"2024-12-30 16:04","pubTimestamp":1735545881,"startTime":"0","endTime":"0","summary":"财中社12月30日电海创药业 发布自愿披露公告,宣布其自主研发的口服PROTAC药物HP568片已获得美国FDA批准,用于治疗ER+/HER2-晚期乳腺癌的临床试验。截至公告披露日,国内外无同类PROTAC产品获批上市。HP568是针对雌激素受体α的靶向药物,具有良好的抗增殖活性和安全性。此次FDA批准的临床试验将进一步验证HP568的有效性,虽然该事件对公司近期业绩不会产生重大影响,但药品研发具有高风险和不确定性。文章来源:财中社海创药业申请HP568片临床试验获FDA批准","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241230161936ab97b489&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241230161936ab97b489&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["688302","BK0239"],"gpt_icon":0},{"id":"2495591403","title":"海创药业(688302.SH):HP568片用于治疗ER+/HER2-晚期乳腺癌临床试验申请获美国FDA批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2495591403","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2495591403?lang=zh_cn&edition=full","pubTime":"2024-12-30 15:39","pubTimestamp":1735544357,"startTime":"0","endTime":"0","summary":"智通财经APP讯,海创药业(688302.SH)公告,公司收到美国食品药品监督管理局(简称“FDA”)的临床研究继续进行通知书,公司自主研发的HP568片用于治疗雌激素受体(ER)阳性和人表皮生长因子受体2(HER2)阴性的晚期乳腺癌(ER+/HER2-晚期乳腺癌)的临床试验申请正式获得FDA批准。此前,HP568片中国同适应症的临床试验申请已于2024年10月获得中国国家药品监督管理局批准。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1230759.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1141","688302","03347","BK1576","BK0239","BK1583"],"gpt_icon":0},{"id":"2494206630","title":"海创药业(688302)12月24日主力资金净卖出867.42万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2494206630","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2494206630?lang=zh_cn&edition=full","pubTime":"2024-12-25 08:23","pubTimestamp":1735086236,"startTime":"0","endTime":"0","summary":"证券之星消息,截至2024年12月24日收盘,海创药业报收于30.86元,下跌1.72%,换手率2.11%,成交量1.54万手,成交额4725.44万元。近5日资金流向一览见下表:海创药业融资融券信息显示,融资方面,当日融资买入213.86万元,融资偿还332.38万元,融资净偿还118.52万元。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024122500007975.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688302","BK0239"],"gpt_icon":0},{"id":"2492044498","title":"海创药业-U12月20日主力资金流出214万元 连续3日减仓","url":"https://stock-news.laohu8.com/highlight/detail?id=2492044498","media":"市场透视","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2492044498?lang=zh_cn&edition=full","pubTime":"2024-12-20 15:20","pubTimestamp":1734679220,"startTime":"0","endTime":"0","summary":"12月20日, 海创药业-U股价涨1.70%,报收32.93元,成交金额2020万元,换手率0.85%,振幅2.96%,量比1.03。海创药业-U今日主力资金净流出214万元,连续3日净流出,上一交易日主力净流出138万元,今日环比增加55.07%。近一年数据显示,该股主力连续3日净流出后,次日下跌概率为40.00%,平均跌幅为2.85%。该股近5个交易日下跌5.37%,主力资金累计净流出615万元,其中2个交易日为股价上涨时净流出;近20日主力资金累计净流出2834万元,其中净流出天数为14日。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241220155221a1fd1c14&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241220155221a1fd1c14&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["688302","BK0239"],"gpt_icon":0},{"id":"2492117559","title":"海创药业-U12月19日遭主力抛售138万元 环比增加1050.00%","url":"https://stock-news.laohu8.com/highlight/detail?id=2492117559","media":"市场透视","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2492117559?lang=zh_cn&edition=full","pubTime":"2024-12-19 15:20","pubTimestamp":1734592801,"startTime":"0","endTime":"0","summary":"12月19日, 海创药业-U股价涨0.15%,报收32.38元,成交金额1192万元,换手率0.51%,振幅2.72%,量比0.55。海创药业-U今日主力资金净流出138万元,上一交易日主力净流出12万元,今日环比增加1050.00%。该股近5个交易日下跌9.33%,主力资金累计净流出641万元,其中1个交易日为股价上涨时净流出;近20日主力资金累计净流出2798万元,其中净流出天数为14日。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241219160503ab83e5ee&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241219160503ab83e5ee&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["688302","BK0239"],"gpt_icon":0},{"id":"2489993420","title":"海创药业遭第二大股东再度减持 上市以来亏损超7亿元","url":"https://stock-news.laohu8.com/highlight/detail?id=2489993420","media":"新京报","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2489993420?lang=zh_cn&edition=full","pubTime":"2024-12-06 12:39","pubTimestamp":1733459950,"startTime":"0","endTime":"0","summary":"作为海创药业的第二大股东,盈创动力所持海创药业股份自2023年6月15日解除限售并上市流通以来,已累计减持1998453股。2024年前三季度,海创药业实现营收10.97万元,亏损1.54亿元。上市不足三年的时间,海创药业已经累计亏损超7亿元。2023年11月29日,海创药业发布公告,再度提交的氘恩扎鲁胺软胶囊新药上市申请被国家药监局药品审评中心受理。截至目前,海创药业的氘恩扎鲁胺软胶囊尚无更新进展。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241206124530ab619e76&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241206124530ab619e76&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK0239","688302"],"gpt_icon":0},{"id":"2489461192","title":"海创药业-U创新低 券商建议增持","url":"https://stock-news.laohu8.com/highlight/detail?id=2489461192","media":"智选洞察","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2489461192?lang=zh_cn&edition=full","pubTime":"2024-12-05 09:30","pubTimestamp":1733362206,"startTime":"0","endTime":"0","summary":"12月05日,海创药业-U股价大幅下跌,截至09点30分,海创药业-U下跌5.36%,报33.03元/股,创近1个月新低,成交115万元,换手率0.05%,振幅2.49%。资金动向截止发稿,海创药业-U获得主力净流出47万元。融资融券方面,海创药业-U12月03日获得融资净买入99万元,当日该股融资余额为5139万元,当较前一日增加1.97%。最新财报显示,今年三季报,海创药业-U实现营业收入10.97万元,同比减少-%,净利润为-1.54亿元,同比增长35.28%,基本每股收益为-1.56元。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024120509305898e5774f&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024120509305898e5774f&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK0239","688302"],"gpt_icon":0},{"id":"2489253464","title":"海创药业股东盈创动力拟减持不超过297万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2489253464","media":"财中社","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2489253464?lang=zh_cn&edition=full","pubTime":"2024-12-05 09:09","pubTimestamp":1733360985,"startTime":"0","endTime":"0","summary":"公告显示,截至2024年12月5日,公司的大股东成都盈创动力创业投资有限公司持有公司股份857万股,占公司总股本的8.6552%。因自身资金需求,盈创动力计划自公告披露之日起十五个交易日后的三个月内,通过集中竞价和大宗交易方式减持公司股份,合计不超过297万股,占公司总股本的3%。盈创动力在过去12个月内已减持156万股,占公司总股本的1.5804%。文章来源:财中社海创药业股东盈创动力拟减持不超过297万股","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241205091910a1d4f1e2&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241205091910a1d4f1e2&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["688302","BK0239"],"gpt_icon":0},{"id":"2488511885","title":"公司热点|频遭二股东减持!多年营收为零 海创药业还要亏损到何时?","url":"https://stock-news.laohu8.com/highlight/detail?id=2488511885","media":"读创财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2488511885?lang=zh_cn&edition=full","pubTime":"2024-12-04 22:45","pubTimestamp":1733323509,"startTime":"0","endTime":"0","summary":"二股东多次减持截至公告披露日,盈创动力持有公司股份856.9996万股,占公司总股本8.6552%,为公司第二大股东。自2023年底以来,盈创动力已先后四次减持海创药业股份。多年营收为零二股东用脚投票下,海创药业多年营收为零且持续亏损。2024年前三季度,公司实现营收11万元,归母净利润亏损1.54亿元。这对急需营收的海创药业来说可谓雪上加霜。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241204230006a26c6d11&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":["earning"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241204230006a26c6d11&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["688302"],"gpt_icon":0},{"id":"2488819616","title":"海创药业:股东盈创动力拟减持不超过3%公司股份","url":"https://stock-news.laohu8.com/highlight/detail?id=2488819616","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2488819616?lang=zh_cn&edition=full","pubTime":"2024-12-04 21:30","pubTimestamp":1733319019,"startTime":"0","endTime":"0","summary":"海创药业公告称,公司持股5%以上的股东成都盈创动力创业投资有限公司(简称“盈创动力”)计划自本公告披露之日起十五个交易日后的三个月内,通过集中竞价交易方式和大宗交易方式减持公司股份合计不超过297.05万股,减持比例不超过公司总股本的3%。以上内容为证券之星据公开信息整理,由智能算法生成,不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024120400039619.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688302","BK0239"],"gpt_icon":0},{"id":"2488196587","title":"海创药业:第二大股东盈创动力拟减持不超3%公司股份","url":"https://stock-news.laohu8.com/highlight/detail?id=2488196587","media":"界面","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2488196587?lang=zh_cn&edition=full","pubTime":"2024-12-04 21:25","pubTimestamp":1733318730,"startTime":"0","endTime":"0","summary":"海创药业12月4日公告,因自身资金需求,第二大股东成都盈创动力创业投资有限公司(以下简称“盈创动力”)计划自公告披露之日起十五个交易日后的三个月内,通过集中竞价交易方式、大宗交易方式减持公司股份合计不超过297.0465万股,合计减持比例不超过公司总股本的3%。其中,通过集中竞价交易方式减持不超过99.0155万股,即不超过公司总股本的1%;通过大宗交易方式减持不超过198.031万股,即不超过公司总股本的2%。截至公告披露日,盈创动力持有公司股份856.9996万股,占公司总股本8.6552%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241204212531abf5a60b&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241204212531abf5a60b&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["688302","BK0239"],"gpt_icon":0},{"id":"2488919581","title":"海创药业(688302.SH):盈创动力拟减持不超3%股份","url":"https://stock-news.laohu8.com/highlight/detail?id=2488919581","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2488919581?lang=zh_cn&edition=full","pubTime":"2024-12-04 21:16","pubTimestamp":1733318187,"startTime":"0","endTime":"0","summary":"智通财经APP讯,海创药业(688302.SH)发布公告,成都盈创动力创业投资有限公司(简称“盈创动力”)计划自本公告披露之日起十五个交易日后的三个月内,通过集中竞价交易方式、大宗交易方式减持公司股份合计不超过297.05万股,合计减持比例不超过公司总股本的3%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1220534.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["688302","BK0239"],"gpt_icon":0},{"id":"2488133966","title":"【机构调研记录】诺安基金调研牧原股份、海创药业等11只个股(附名单)","url":"https://stock-news.laohu8.com/highlight/detail?id=2488133966","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2488133966?lang=zh_cn&edition=full","pubTime":"2024-12-02 08:03","pubTimestamp":1733097783,"startTime":"0","endTime":"0","summary":"证券之星消息,根据市场公开信息及11月29日披露的机构调研信息,诺安基金近期对11家上市公司进行了调研,相关名单如下:1)牧原股份 个股亮点:公司是我国境内最大的自育自繁自养一体化的生猪养殖企业之一;牧原转债于2021-09-10上市;公司与元素驱动合作成立了河南牧元安粮公司,年产3万吨合成生物项目已开工。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024120200001057.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","BK0196","BK0187","BK0070","BK0028","BK0056","BK0195","688302","002714","BK0197","BK0240"],"gpt_icon":0},{"id":"2488561337","title":"【机构调研记录】安信基金调研海创药业、华测检测等4只个股(附名单)","url":"https://stock-news.laohu8.com/highlight/detail?id=2488561337","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2488561337?lang=zh_cn&edition=full","pubTime":"2024-12-02 08:02","pubTimestamp":1733097735,"startTime":"0","endTime":"0","summary":"证券之星消息,根据市场公开信息及11月29日披露的机构调研信息,安信基金近期对4家上市公司进行了调研,相关名单如下:1)海创药业 个股亮点:公司是一家基于氘代技术和PROTAC靶向蛋白降解等技术平台,专注于肿瘤、代谢性疾病等重大治疗领域的创新药物研发。以上内容为证券之星据公开信息整理,由智能算法生成,不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024120200001007.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["LU2460026573.USD","688302","LU1146622755.USD","LU1820825898.SGD","BK0159","BK0132","300012","BK0221","BK0239"],"gpt_icon":0},{"id":"2488613374","title":"【机构调研记录】嘉实基金调研歌力思、海创药业等14只个股(附名单)","url":"https://stock-news.laohu8.com/highlight/detail?id=2488613374","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2488613374?lang=zh_cn&edition=full","pubTime":"2024-12-02 08:02","pubTimestamp":1733097726,"startTime":"0","endTime":"0","summary":"证券之星消息,根据市场公开信息及11月29日披露的机构调研信息,嘉实基金近期对14家上市公司进行了调研,相关名单如下:1)歌力思 个股亮点:公司线上销售的主营业务收入占比为10.15%;公司在2022年4月22日发布300个NFT收藏藏品;公司百秋网络运营模式包括网红带货2)海创药业 个股亮点:公司是一家基于氘代技术和PROTAC靶向蛋白降解等技术平台,专注于肿瘤、代谢性疾病等重大治疗领域的创新药物研发。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024120200000999.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688302","BK0253","BK0070","BK0239","603808","BK0201"],"gpt_icon":0},{"id":"2488618093","title":"【机构调研记录】兴业基金调研海创药业、福光股份等7只个股(附名单)","url":"https://stock-news.laohu8.com/highlight/detail?id=2488618093","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2488618093?lang=zh_cn&edition=full","pubTime":"2024-12-02 08:01","pubTimestamp":1733097690,"startTime":"0","endTime":"0","summary":"证券之星消息,根据市场公开信息及11月29日披露的机构调研信息,兴业基金近期对7家上市公司进行了调研,相关名单如下:1)海创药业 个股亮点:公司是一家基于氘代技术和PROTAC靶向蛋白降解等技术平台,专注于肿瘤、代谢性疾病等重大治疗领域的创新药物研发。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024120200000968.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","BK0225","688010","688302"],"gpt_icon":0},{"id":"2486499336","title":"海创药业-U 涨5.44%","url":"https://stock-news.laohu8.com/highlight/detail?id=2486499336","media":"智选洞察","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2486499336?lang=zh_cn&edition=full","pubTime":"2024-11-28 09:31","pubTimestamp":1732757477,"startTime":"0","endTime":"0","summary":"11月28日,海创药业-U股价大幅上涨,截至09点31分,海创药业-U上涨5.44%,报37.38元/股,成交410万元,换手率0.16%,振幅4.51%。资金动向截止发稿,海创药业-U获得主力净流入68万元,其中超大单流出49万元,大单流入117万元。最新财报显示,今年三季报,海创药业-U实现营业收入10.97万元,同比减少-%,净利润为-1.54亿元,同比增长35.28%,基本每股收益为-1.56元。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241128093539abe4894b&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241128093539abe4894b&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["688302","BK0239"],"gpt_icon":0}],"profile":{"ret":0,"listingDate":"2022-04-12","address":"四川省成都市武侯区高新区科园南路5号蓉药大厦1栋4层附2、3号","stockEarnings":[{"period":"1week","weight":-0.0296},{"period":"1month","weight":-0.1543},{"period":"3month","weight":-0.1513},{"period":"6month","weight":0.2232},{"period":"1year","weight":-0.4148},{"period":"ytd","weight":-0.4148}],"companyName":"海创药业股份有限公司","boardCode":"AI0027","perCapita":"18383股","boardName":"医药制造业","registeredCapital":"9901万元","compareEarnings":[{"period":"1week","weight":0.0167},{"period":"1month","weight":0.0243},{"period":"3month","weight":0.0212},{"period":"6month","weight":0.1425},{"period":"1year","weight":0.1453},{"period":"ytd","weight":0.1453}],"survey":" 海创药业股份有限公司是一家基于氘代技术和PROTAC靶向蛋白降解等技术平台,以开发具有重大临床需求的Best-in-class(同类最佳)、First-in-class(国际首创)药物为目标的国际化创新药企业。公司的主要产品为肿瘤、代谢性疾病药品。公司在肿瘤和代谢性疾病领域重点布局,重点搭建了氘代药物研发平台、PROTAC靶向蛋白降解技术平台、靶向药物发现与验证平台与先导化合物优化筛选平台,形成了较强的研发优势和丰富的技术储备。","serverTime":1735597758769,"listedPrice":42.92,"stockholders":"3956人(较上一季度增加14.80%)","compareStock":{"symbol":"000001.SH","name":"上证指数"}},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.29.4","shortVersion":"4.29.4","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"海创药业(688302)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供海创药业(688302)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"海创药业,688302,海创药业股票,海创药业股票老虎,海创药业股票老虎国际,海创药业行情,海创药业股票行情,海创药业股价,海创药业股市,海创药业股票价格,海创药业股票交易,海创药业股票购买,海创药业股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"海创药业(688302)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供海创药业(688302)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}